Compare MasterCard Inc (MA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs State Street SPDR S&P Biotech ETF — how do they compare? MasterCard Inc trades at $583.74 (market cap $503.50B), while State Street SPDR S&P Biotech ETF trades at $152.16 (market cap $10.11B). The key difference: MasterCard Inc is far larger — about 49.8× State Street SPDR S&P Biotech ETF's market cap, and MasterCard Inc pays a 0.61% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 134 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| MA | XBI | |
|---|---|---|
Market Cap | $503.50B | $10.11B |
Volume | 3,390,859 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $599.86 | $169.55 |
52-Week Low | $471.55 | $104.99 |
Typical Hold Time | 134 Days | 37 Days |
Enterprise Value | $516.53B | — |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $570.06, up 0.61% with strong technical and fundamental momentum. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth accelerated to $32.79B in 2025 with impressive 46.34% net margins, though valuation multiples remain elevated with P/E at 31.61. Recent institutional buying activity and positive analyst coverage support the upward trend.
Mastercard presents a compelling growth story with expanding global payment volumes and digital transformation initiatives. The primary investment thesis centers on continued market share gains and margin expansion, though risks include payment industry disruption from stablecoins and elevated valuation multiples requiring sustained high growth. Analyst consensus targets $666.67 suggest 17% upside potential from current levels.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
